Paternal Valproate Treatment and Risk of Childhood Neurodevelopmental Disorders: Precautionary Regulatory Measures Are Insufficiently Substantiated.
Joan D GareyPer DamkierAnthony R ScialliShari LusskinStephen R BraddockLaurent ChouchanaBrian ClearyElizabeth A ConoverOrna Diav-CitrinRachel S DragovichFacundo Garcia-BournissenKen HodsonDebra KennedySteven H LammSharon A LavigneSarah G ObičanAlice PanchaudKirstie PerrottaAlfred N RomeoSvetlana ShechtmanCorinna Weber-SchoendorferPublished in: Birth defects research (2024)
On January 12, 2024 the safety committee of the European Medicines Agency (EMA) recommended precautionary measures over a potential risk of neurodevelopmental disorders in children born to men treated with valproate. These new measures recommend patient supervision by a specialist in the management of epilepsy, bipolar disorder, or migraine. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a far more stringent precaution, warning against prescribing valproate to anyone under 55 years of age. We, members of the European Network of Teratology Information Services (ENTIS) and the Organization of Teratology Information Specialists (OTIS), believe that the EMA and MHRA warnings were premature. We are of the opinion that the underlying scientific data do not convincingly substantiate the inference of a paternally mediated risk from valproate to children, much less to an extent that justifies these far-reaching recommendations.
Keyphrases
- healthcare
- bipolar disorder
- primary care
- young adults
- transcription factor
- health information
- major depressive disorder
- palliative care
- case report
- emergency department
- low birth weight
- gestational age
- single cell
- preterm infants
- big data
- risk assessment
- congenital heart disease
- childhood cancer
- cross sectional
- human health
- social media
- artificial intelligence
- drug administration
- replacement therapy
- breast cancer risk